In vitro and in vivo analysis of the human cyp3a5 promoter

被引：0
|
作者：
Nem, D. [1 ]
Qiu, H. [1 ]
Nestler, S. [1 ]
Goedtel-Armbrust, U. [1 ]
Wojnowski, L. [1 ]
机构：
[1] Univ Med Mainz, Mainz, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2010年 / 381卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [1] In vitro metabolism of cyclosporine A by human kidney CYP3A5
    Dai, Y
    Iwanaga, K
    Lin, YS
    Hebert, MF
    Davis, CL
    Huang, WL
    Kharasch, ED
    Thummel, KE
    BIOCHEMICAL PHARMACOLOGY, 2004, 68 (09) : 1889 - 1902
  • [2] In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans
    Hirota, N
    Ito, K
    Iwatsubo, T
    Green, CE
    Tyson, CA
    Shimada, N
    Suzuki, H
    Sugiyama, Y
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2001, 22 (02) : 53 - 71
  • [3] In vitro metabolism of cyclosporine A by human kidney microsomal CYP3A5
    Dai, Y
    Iwanaga, K
    Lin, YS
    Huang, W
    Thummel, KE
    DRUG METABOLISM REVIEWS, 2003, 35 : 188 - 188
  • [4] Atazanavir Metabolism According to CYP3A5 Status: An In Vitro-In Vivo Assessment
    Wempe, Michael F.
    Anderson, Peter L.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (03) : 522 - 527
  • [5] CYP3A5 EXPRESSION IN HUMAN ENTEROCYTES
    JANARDAN, SK
    LOWN, KS
    GHOSH, M
    KOLARS, JC
    WATKINS, PB
    GASTROENTEROLOGY, 1994, 106 (04) : A241 - A241
  • [6] Selective metabolism of vincristine in vitro by CYP3A5
    Dennison, Jennifer B.
    Kulanthaivel, Palaniappan
    Barbuch, Robert J.
    Renbarger, Jamie L.
    Ehlhardt, William J.
    Hall, Stephen D.
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (08) : 1317 - 1327
  • [7] CYP3A5 Genotype-Phenotype Analysis in the Human Kidney Reveals a Strong Site-Specific Expression of CYP3A5 in the Proximal Tubule in Carriers of the CYP3A5*1 Allele
    Bolbrinker, Juliane
    Seeberg, Stefanie
    Schostak, Martin
    Kempkensteffen, Carsten
    Baelde, Hans
    de Heer, Emile
    Kreutz, Reinhold
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 639 - 641
  • [8] Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus
    Kamdem, LK
    Streit, F
    Zanger, UM
    Brockmöller, J
    Oellerich, M
    Armstrong, VW
    Wojnowski, L
    CLINICAL CHEMISTRY, 2005, 51 (08) : 1374 - 1381
  • [9] Analysis of CYP3A5*3 and CYP3A5*6 Gene Polymorphisms in Indian Chronic Myeloid Leukemia Patients
    Sailaja, K.
    Surekha, D.
    Rao, D. Nageswara
    Rao, D. Raghunadha
    Vishnupriya, S.
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2010, 11 (03) : 781 - 784
  • [10] GLOBAL ANALYSIS OF CYP3A4 AND CYP3A5 GENOTYPE ON IN VIVO CLEARANCE OF CYP3A4 SUBSTRATES.
    Quinney, S. K.
    Schwartz, J. B.
    Hall, S. D.
    Gorski, J. C.
    Li, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S49 - S49
12345